<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>For over 50 years, <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> has been recognized as an important trigger of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0001856'>myocarditis</z:mp>, inflammatory <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) and <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Nevertheless, <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> remains challenging to diagnose and treat </plain></SENT>
<SENT sid="2" pm="."><plain>Improved diagnostic methods for <z:mp ids='MP_0001856'>myocarditis</z:mp> have led to a better understanding of its pathophysiology </plain></SENT>
<SENT sid="3" pm="."><plain>The recognition of virus-mediated damage, <z:mp ids='MP_0001845'>inflammation</z:mp> and autoimmune dysregulation in these patients highlights the importance of differentiating between virus-positive and virus-negative inflammatory <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>These insights have led to the development of novel treatment strategies, including intravenous immunoglobulin and interferon therapy for virus-positive patients </plain></SENT>
<SENT sid="5" pm="."><plain>This article will focus on the pathogenesis of <z:mp ids='MP_0001799'>viral</z:mp> <z:mp ids='MP_0001856'>myocarditis</z:mp>, especially parvovirus B19-induced, its progression to inflammatory <z:chebi fb="20" ids="15767">DCM</z:chebi> and future treatment strategies </plain></SENT>
</text></document>